II. Indications
- Venous Thromboembolism (DVT, PE) prophylaxis and treatment
- Acute Coronary Syndrome
III. Mechanism
IV. Dosing: Prophylactic Dose
-
Creatinine Clearance (CrCl) >30 ml/min AND Weight 40-150 kg
- Enoxaparin (Lovenox) 40 mg SQ daily for medical inpatients or abdominal surgery
- Enoxaparin (Lovenox) 30 mg SQ every 12 hours if s/p knee or hip replacement
-
Creatinine Clearance (CrCl) >30 ml/min AND Weight >150 kg (or BMI 40 of higher)
- Enoxaparin (Lovenox) 40 mg SQ twice daily
-
Creatinine Clearance (CrCl) 15-30 ml/min (or weight <40 kg)
- Enoxaparin (Lovenox) 30 mg SQ daily
-
Creatinine Clearance (CrCl) <15 ml/min
- Enoxaparin (Lovenox) is contraindicated
- Use unfractionated heaprin 5000 units SQ every 8-12 hours
V. Dosing: Therapeutic Dose
-
Creatinine Clearance (CrCl) >30 ml/min
- Enoxaparin (Lovenox) 1 mg/kg SQ every 12 hours OR
- Enoxaparin (Lovenox) 1.5 mg/kg SQ every 24 hours for inpatients with acute VTE (DVT, PE)
-
Creatinine Clearance (CrCl) 15-30 ml/min (or weight <40 kg)
- Unfractionated Heparin is preferred
- As an alternative, Enoxaparin (Lovenox) 1 mg/kg SQ once daily for up to 7 days
-
Creatinine Clearance (CrCl) <15 ml/min
- Enoxaparin (Lovenox) is contraindicated
- Use Unfractionated Heparin 5000 units SQ every 8-12 hours
VI. Safety
- Use in pregnancy when benefit outweighs the risk
- Considered safe in Lactation
VII. Efficacy
VIII. Resources
IX. References
- Dummer (2009) Perioperative Guidelines
- Douketis (2008) Chest 133(6 Suppl):299S-339S [PubMed]
Images: Related links to external sites (from Bing)
Related Studies
enoxaparin (on 12/21/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
ENOXAPARIN 100 MG/ML SYRINGE | Generic | $10.14 per ml |
ENOXAPARIN 120 MG/0.8 ML SYR | Generic | $17.75 per ml |
ENOXAPARIN 150 MG/ML SYRINGE | Generic | $16.75 per ml |
ENOXAPARIN 30 MG/0.3 ML SYR | Generic | $12.43 per ml |
ENOXAPARIN 300 MG/3 ML VIAL | Generic | $13.43 per ml |
ENOXAPARIN 40 MG/0.4 ML SYR | Generic | $12.12 per ml |
ENOXAPARIN 60 MG/0.6 ML SYR | Generic | $10.70 per ml |
ENOXAPARIN 80 MG/0.8 ML SYR | Generic | $10.14 per ml |
Ontology: Enoxaparin (C0206460)
Definition (NCI_NCI-GLOSS) | A drug used to prevent blood clots. It belongs to the family of drugs called anticoagulants. |
Definition (NCI) | A low molecular weight, synthetic heparin. As an anticoagulant/antithrombotic agent, enoxaprin's mechanism of action is similar to that of heparin, although it exhibits a higher ratio of anti-Factor Xa to anti-Factor IIa activity. This agent also has anti-inflammatory properties, inhibiting monocyte adhesion to tumor necrosis factor alpha- or lipopolysaccharide-activated endothelial cells. Compared to unfractionated heparins, the use of enoxaparin is associated with lower incidences of osteoporosis and heparin-induced thrombocytopenia. (NCI04) |
Definition (MSH) | Low-molecular-weight fragment of heparin, having a 4-enopyranosuronate sodium structure at the non-reducing end of the chain. It is prepared by depolymerization of the benzylic ester of porcine mucosal heparin. Therapeutically, it is used as an antithrombotic agent. (From Merck Index, 11th ed) |
Definition (PDQ) | A low molecular weight, synthetic heparin. As an anticoagulant/antithrombotic agent, enoxaprin's mechanism of action is similar to that of heparin, although it exhibits a higher ratio of anti-Factor Xa to anti-Factor IIa activity. This agent also has anti-inflammatory properties, inhibiting monocyte adhesion to tumor necrosis factor alpha- or lipopolysaccharide-activated endothelial cells. Compared to unfractionated heparins, the use of enoxaparin is associated with lower incidences of osteoporosis and heparin-induced thrombocytopenia. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37880&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37880&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1452" NCI Thesaurus) |
Concepts | Pharmacologic Substance (T121) , Carbohydrate (T118) |
MSH | D017984 |
SnomedCT | 108984007, 372562003 |
English | Enoxaparin, Enoxaparine, enoxaparin (medication), Enoxaparin [Chemical/Ingredient], enoxaparine, ENOXAPARIN, enoxaparin, Enoxaparin (product), Enoxaparin (substance) |
Swedish | Enoxaparin |
Czech | enoxaparin |
Finnish | Enoksapariini |
Italian | Enoxaparine, Enoxaparina |
Russian | ENOKSAPARIN, ЭНОКСАПАРИН |
Japanese | エノキサパリン |
Polish | Enoksaparyna |
Croatian | Enoksaparin |
Spanish | enoxaparina (producto), enoxaparina (sustancia), enoxaparina, Enoxaparina |
French | Énoxaparine |
German | Enoxaparin |
Portuguese | Enoxaparina |
Ontology: Lovenox (C0728963)
Definition (CHV) | brand name of enoxaparin |
Definition (CHV) | brand name of enoxaparin |
Concepts | Pharmacologic Substance (T121) , Carbohydrate (T118) |
MSH | D017984 |
English | Lovenox [brand name], Lovenox |